Acute supplementation with eicosapentaenoic acid reduces platelet microparticle activity in healthy subjects

Phang, Melinda; Lincz, Lisa F.; Seldon, Michael; Garg, Manohar L.

doi:10.1016/j.jnutbio.2011.06.006

Cited by 27 publications

(20 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Del Turco et al (24) had shown that both platelet MP number and activity were decreased in patients supplemented with Omega-3 for 12 weeks after a myocardial infarction. However, Phang et al (28) later showed that a single dose of EPA in healthy people reduced platelet MP activity, possibly due to EPA incorporation into the platelet membrane, without altering platelet MP count, which is consistent with our previous data (26,27).…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

An Intravenous Bolus of Epa

Burban

Meyer

Olland

et al. 2016

Shock

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

“…Altogether, these reports already suggested that MP activity might be immediately altered by the incorporation of Omega-3 into the platelet membrane, while MP generation might be decreased only after long-term exposition to fatty acids (28).…”

Section: Discussionmentioning

confidence: 90%

An Intravenous Bolus of Epa

Burban

Meyer

Olland

et al. 2016

Shock

View full text Add to dashboard Cite

show abstract

“…Changes induced by O3FA at the membrane and intracellular levels also lead to inhibited platelet function through augmentation of the negative surface charge density, modulation of signal-transduction molecules, and decreased adhesiveness and granule secretion 5,18–20 . The inhibitory effect of O3FA on pro-coagulant platelet- and monocyte-derived microparticles has also been described in specific situations 21,22 . Additionally, EPA and DHA can decrease platelet-mediated thrombin generation, thereby acting indirectly on the coagulation cascade 23 .…”

Section: Discussionmentioning

confidence: 95%

Risk of post-procedural bleeding in children on intravenous fish oil

Nandivada

Anez‐Bustillos

O’Loughlin

et al. 2017

The American Journal of Surgery

View full text Add to dashboard Cite

Background Intestinal failure-associated liver disease (IFALD) can be treated with parenteral fish oil (FO) monotherapy, but practitioners have raised concerns about a potential bleeding risk. This study aims to describe the incidence of clinically significant post-procedural bleeding (CSPPB) in children receiving FO monotherapy. Methods A retrospective chart review was performed on patients at our institution treated with intravenous FO for IFALD. CSPPB was defined as bleeding leading to re-operation, transfer to the intensive care unit, re-admission, or death, up to one month after any invasive procedure. Results From 244 patients reviewed, 183 underwent ≥1 invasive procedure (n=732). Five (0.68%, 95% CI 0.22–1.59%) procedures resulted in CSPPB. FO therapy was never interrupted. No deaths occurred. Conclusions Findings suggest that FO therapy is safe, with a CSPPB risk no greater than that reported in the general population. O3FA should not be held in preparation for procedures or in the event of bleeding.

show abstract

“…The heterogeneity of platelet concentrates increases with storage [10, 13, 32, 33] and with pathogen-reduction processing [5, 13] and varies greatly between normal donors [13, 34–36]. The largest contributor to platelet heterogeneity is the microparticle content (Figure 1(b)).…”

Section: Platelet Quality From the Perspective Of Productionmentioning

confidence: 99%

Could Microparticles Be the Universal Quality Indicator for Platelet Viability and Function?

Maurer‐Spurej

Chipperfield

2016

Journal of Blood Transfusion

View full text Add to dashboard Cite

High quality means good fitness for the intended use. Research activity regarding quality measures for platelet transfusions has focused on platelet storage and platelet storage lesion. Thus, platelet quality is judged from the manufacturer's point of view and regulated to ensure consistency and stability of the manufacturing process. Assuming that fresh product is always superior to aged product, maintaining in vitro characteristics should preserve high quality. However, despite the highest in vitro quality standards, platelets often fail in vivo. This suggests we may need different quality measures to predict platelet performance after transfusion. Adding to this complexity, platelets are used clinically for very different purposes: platelets need to circulate when given as prophylaxis to cancer patients and to stop bleeding when given to surgery or trauma patients. In addition, the emerging application of platelet-rich plasma injections exploits the immunological functions of platelets. Requirements for quality of platelets intended to prevent bleeding, stop bleeding, or promote wound healing are potentially very different. Can a single measurable characteristic describe platelet quality for all uses? Here we present microparticle measurement in platelet samples, and its potential to become the universal quality characteristic for platelet production, storage, viability, function, and compatibility.

show abstract

Acute supplementation with eicosapentaenoic acid reduces platelet microparticle activity in healthy subjects

Cited by 27 publications

References 43 publications

An Intravenous Bolus of Epa

An Intravenous Bolus of Epa

Risk of post-procedural bleeding in children on intravenous fish oil

Could Microparticles Be the Universal Quality Indicator for Platelet Viability and Function?

Contact Info

Product

Resources

About